In a move that cements 2025 as the year of the megadeal, Hologic Inc. — the women’s health-focused medical technology company — announced Tuesday that it will be acquired by private equity giants Blackstone and TPG in a blockbuster deal valuing the company at $18.3 billion.
The transaction, one of the largest leveraged healthcare buyouts in recent memory, will see Blackstone and TPG purchase all outstanding shares of Hologic for $76 per share in cash, plus a nontradable contingent value right worth up to $3 per share, tied to performance milestones in Hologic’s breast health business through 2027.
The deal also welcomes minority investments from the Abu Dhabi Investment Authority and Singapore’s GIC, reinforcing global investor appetite for major healthcare assets.
A Transformational Moment for Women’s Health Leader
Wachtell Lipton Rosen & Katz is advising Hologic, while Kirkland & Ellis LLP represents the Blackstone–TPG consortium, with Ropes & Gray LLP handling healthcare regulatory matters for the private equity firms.
“Today marks an exciting new chapter for Hologic as we join forces with the exceptional teams at Blackstone and TPG,” said Stephen P. MacMillan, Hologic’s chair, president, and CEO. “This transaction delivers immediate and compelling value to our stockholders.”
Based in Marlborough, Massachusetts, Hologic develops diagnostic tests, imaging systems, and surgical products that focus primarily on women’s health, including breast cancer screening and gynecological innovations. The company will continue to operate under its existing name after the deal closes.
